// Company Overview //
| Stock Name | 現代中藥集團有限公司 |
| Stock Code | 01643 |
| Company Full Name | 現代中藥集團有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事生產中成藥。 |
| Listing Date | 2021-01-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國河北省承德市津圍公路88號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.cdysjdyy.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2020-12-31 |
| Offer Price | HK$ 1.18 / shares |
| Total Funds Raised | HK$ 53,100,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
// First Day Performance
| First Day Close | Loading... |
| First Day Open | HK$ 1.17 |
| First Day Change | 6.78% |
| First Day Volume | 83169000.0 |
| First Day Turnover | 103949000.0 |
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、約44.0%或51.7百萬港元將用于提高及擴大產能,進一步生產我們的主要膠囊處方藥;
2、約16.8%或19.7百萬港元將用于擴大我們華南及華東的分銷網絡;
3、約10.2%或12.0百萬港元將用于提高品牌知名度,方法為媒體營銷及推廣;
4、約19.9%或23.4百萬港元將用于進一步加大研發力度、采購質量管理設備及 擴大產品組合,長遠而言為業務增值;
5、約3.4%或4.0百萬港元將用于升級IT系統;
6、約5.7%或6.6百萬港元將撥作營運資金及用作其他一般公司用途。 |
// Underwriting Syndicate //
整体协调人 (2)
东吴证券国际经纪有限公司
富汇证券有限公司
联席账簿管理人 (8)
东吴证券国际经纪有限公司
富汇证券有限公司
浦银国际融资有限公司
交银国际证券有限公司
越秀证券有限公司
山证国际证券有限公司
申万宏源证券(香港)有限公司
千里硕证券有限公司
联席牵头经办人 (13)
东吴证券国际经纪有限公司
富汇证券有限公司
浦银国际融资有限公司
交银国际证券有限公司
越秀证券有限公司
山证国际证券有限公司
申万宏源证券(香港)有限公司
千里硕证券有限公司
中募金融资管有限公司
德林证券(香港)有限公司
方德证券有限公司
中国北方证券集团有限公司
富元证券有限公司
// Cornerstone Investors //
This stock has no cornerstone investors.
// Directors & Management //
| Chairman | 孫新磊 |
| Company Secretary | 謝婉婷,賈艷茹 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 現代生物科技集團控股有限公司(75%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.